KRAS and cancer: Another report showed in preclinical models that combining a BRAF dimer inhibitor with an MEK inhibitor induced a dramatic therapeutic effect and overcame acquired resistance among cancers with KRAS, NRAS, NF1, BRAF non-V600E, and BRAF V600E mutations.